The IL‐17 level in the serum of CTEPH patients (19.25 ± 3.06 pg/mL) was higher than that in the control group (13.33 ± 2.636 pg/mL), with a statistically significant difference (p < 0.001) (Figure 1). Here, IL17A is linked to chronic thromboembolic pulmonary hypertension.